The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zaidieva Ya.Z.

Moscow Regional Research Institute of Obstetrics and Gynecology

Kazantseva V.D.

Moscow Regional Research Institute of Obstetrics and Gynecology

Comparative analysis of the prevalence of abnormal uterine bleeding in postmenopausal women against the background of various menopausal hormone therapy (systematic review)

Authors:

Zaidieva Ya.Z., Kazantseva V.D.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2021;21(6): 51‑58

DOI: 10.17116/rosakush20212106151

Views: 1373

Downloaded: 33

Download PDF (RU)
Contact the author
Table of contents

COMPARATIVE ANALYSIS OF THE PREVALENCE OF ABNORMAL UTERINE BLEEDING IN POSTMENOPAUSAL WOMEN AGAINST THE BACKGROUND OF VARIOUS MENOPAUSAL HORMONE THERAPY (SYSTEMATIC REVIEW)
COMPARATIVE ANALYSIS OF THE PREVALENCE OF ABNORMAL UTERINE BLEEDING IN POSTMENOPAUSAL WOMEN AGAINST THE BACKGROUND OF VARIOUS MENOPAUSAL HORMONE THERAPY (SYSTEMATIC REVIEW)

To cite this article:

Zaidieva YaZ, Kazantseva VD. Comparative analysis of the prevalence of abnormal uterine bleeding in postmenopausal women against the background of various menopausal hormone therapy (systematic review). Russian Bulletin of Obstetrician-Gynecologist. 2021;21(6):51‑58. (In Russ.)
https://doi.org/10.17116/rosakush20212106151

Подписка 2025-2 (Russian Bulletin of Obstetrician-Gynecologist)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Acute gyne­cologic pathology in patients with COVID-19. Russian Bulletin of Obstetrician-Gynecologist. 2024;(4):56-62
Features of the clinical picture of affe­ctive diso­rders in women during the meno­pausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79
Pathophysiological mechanisms of vascular wall alte­rations in meno­pausal women. Russian Journal of Preventive Medi­cine. 2024;(6):91-97
Awareness of women about the prevention and correction of climacteric diso­rders. Russian Journal of Preventive Medi­cine. 2025;(1):57-62

Abnormal uterine bleeding in postmenopausal women is the most common cause of interrupting menopausal hormone therapy (MHT). This systematic review compared bleeding events reported in studies of continuous combined MHT for the treatment of moderate to severe vasomotor symptoms in postmenopausal women. Studies have shown that the incidence of uterine bleeding differs depending on the choice of the drug and the route of administration, while with oral administration of the drug there are fewer cases of bleeding than with transdermal. Amenorrhea throughout the year ranged from 18 to 61% with oral MHT and from 9 to 27% with transdermal MHT. Oral administration of the drug containing the E2/P4 combination has the lowest incidence of bleeding.

Keywords:

amenorrhea
continuous-combined hormone therapy
menopause
abnormal uterine bleeding
vasomotor symptoms

Authors:

Zaidieva Ya.Z.

Moscow Regional Research Institute of Obstetrics and Gynecology

Kazantseva V.D.

Moscow Regional Research Institute of Obstetrics and Gynecology

Received:

26.02.2021

Accepted:

29.03.2021

List of references:

  1. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24:7:728-753.  https://doi.org/10.1097/GME.0000000000000921
  2. Archer D. Endometrial bleeding in postmenopausal women: with and without hormone therapy. Menopause. 2011;18:4:416-420.  https://doi.org/10.1097/gme.0b013e31820ca808
  3. Arbuckle R, Humphrey L, Abraham L, Dennerstein L, Mirkin S, Bonner N, Walmsley S, Tatlock S, Symonds T. Qualitative cross-cultural exploration of vaginal bleeding/spotting symptoms and impacts associated with hormone therapy in post-menopausal women to inform the development of new patient-reported measurement tools. Maturitas. 2014;78:3:219-227.  https://doi.org/10.1016/j.maturitas.2014.04.019
  4. Newton K, Reed S, Nekhyludov L, Enrlich K, LaCroix A. Factors associated with successful discontinuation of hormone therapy. J Womens Health (Larchmt). 2014;23:5:382-388.  https://doi.org/10.1089/jwh.2012.4200
  5. Welton A, Vickers M, Kim J, Martin J, Ford D, Meredith S, MacLennan A. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ. 2008;337:a1190. https://doi.org/10.1136/bmj.a1190
  6. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev. 2004;3:CD000402. https://doi.org/10.1002/14651858.CD000402.pub2
  7. Archer D, Dorin M, Lewis V, Schneider D, Pickar J. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 2001;75:6:1080-1087. https://doi.org/10.1016/s0015-0282(01)01792-7
  8. Rowan J, Simon J, Speroff L, Ellman H. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. Clin Ther. 2006;28:6:921-932.  https://doi.org/10.1016/j.clinthera.2006.06.013
  9. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA. 1996;276:17:1397-1403.
  10. Archer D, Dorin M, Heine W, Nanavati N, Arce J. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol. 1999;94:3:323-329.  https://doi.org/10.1016/s0029-7844(99)00358-0
  11. Yildirim G, Tugrul S, Uslu H, Pekin O, Eren S. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. Arch Gynecol Obstet. 2006;273:5:268-273.  https://doi.org/10.1007/s00404-005-0099-6
  12. Hammar M, van de Weijer P, Franke H, Porner B, Nijland E. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG. 2007;114:12:1522-1529. https://doi.org/10.1111/j.1471-0528.2007.01537.x
  13. Samsioe G, Dvorak V, Genazzani A, Hamann B, Suzin J, Mueck A. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. Maturitas. 2007;57:2:171-181.  https://doi.org/10.1016/j.maturitas.2007.01.001
  14. Genazzani R, Schmelter T, Schaefers M, Gerlinger G. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women. Climacteric. 2013;16:4:495-498.  https://doi.org/10.3109/13697137.2013.783797
  15. Bouchard P, De Cicco-Nardone F, Spielmann D, Garcea N. Trimegestone 301 Study Group. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women. Gynecol Endocrinol. 2005;21:3:142-148.  https://doi.org/10.1080/09513590500168464
  16. Hammar M., Christau S., Nathorst-Böös J., Rud T., Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998;105:8:904-911.  https://doi.org/10.1111/j.1471-0528.1998.tb10237.x
  17. Mattsson L, Bohnet H, Gredmark T, Torhorst J, Hornig F, Hüls G. Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. Obstet Gynecol. 1999;94:1:61-65.  https://doi.org/10.1016/s0029-7844(99)00225-2
  18. Dören M, Rübig A, Coelingh Bennink H, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause. 1999;6:4:299-306.  https://doi.org/10.1097/00042192-199906040-00005
  19. Gräser T, Koytchev R, Müller A, Oettel M. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women. Climacteric. 2000;3:2:109-118.  https://doi.org/10.3109/13697130009167612
  20. Rozenberg S, Caubel P, Lim P. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. Int J Gynaecol Obstet. 2001;72:3:235-243.  https://doi.org/10.1016/s0020-7292(00)00342-8
  21. Odmark I, Jonsson B, Bäckström T. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate. Am J Obstet Gynecol. 2001;184:6:1131-1138. https://doi.org/10.1067/mob.2001.112561
  22. Archer D, Thorneycroft I, Foegh M, Michael D, Pincas B, Richard L. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005;12:6:716-727.  https://doi.org/10.1097/01.gme.0000177318.24005.b1
  23. Stevenson J, Durand G, Kahler E, Pertyński T. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas. 2010;67:3:227-232.  https://doi.org/10.1016/j.maturitas.2010.07.002
  24. Pickar J, Bottiglioni F, Archer D. Amenorrhea frequency with continuous combined hormone replacement therapy: a retrospective analysis. Menopause Study Group. Climacteric. 1998;1:2:130-136.  https://doi.org/10.3109/13697139809085528
  25. Archer D, Pickar J. Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding. Obstet Gynecol. 2000;96:6:899-905.  https://doi.org/10.1016/s0029-7844(00)01036-x
  26. Baracat E, Barbosa I, Giordano M, Haidar M, Marinho R, Tomaz G, Wehba S. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric. 2002;5:1:60-69. 
  27. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. J Br Menopause Soc. 2004;10:3:95-102.  https://doi.org/10.1258/1362180043654647
  28. Mattsson L, Skouby S, Rees M, Mustonen M, Salminen K, Vuorela A. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women. Menopause Int. 2007;13:3:124-131.  https://doi.org/10.1258/175404507781605596
  29. Shulman L, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause. 2002;9:3:195-207.  https://doi.org/10.1097/00042192-200205000-00008
  30. Archer D, Furst K, Tipping D, Dain M, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol. 1999;94:4:498-503.  https://doi.org/10.1016/s0029-7844(99)00359-2
  31. Ylikorkala O, Rozenberg S. Efficacy and tolerability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women. Maturitas. 2000;37:2:83-93.  https://doi.org/10.1016/s0378-5122(00)00155-9
  32. Oosterbaan H, van Buuren A, Schram J, Beyer G, Ubachs J. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas. 1995;21:3:211-219.  https://doi.org/10.1016/0378-5122(94)00891-a
  33. Stevenson J, Teter P, Lees B. 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. Maturitas. 2001;38:2:197-203.  https://doi.org/10.1016/s0378-5122(00)00219-x
  34. Ain Melk Y. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. Fertil Steril. 1996;66:6:962-968.  https://doi.org/10.1016/s0015-0282(16)58690-7
  35. Archer D, Pickar J, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol. 1994;83:5 Pt 1:686-692. 
  36. Jirapinyo M, Theppisai U, Manonai J, Suchartwatnachai C, Jorgensen L. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women. Acta Obstet Gynecol Scand. 2003;82:9:857-866. 
  37. Mirkin S, Komm B, Pan K, Chines A. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric. 2013;16:3:338-346.  https://doi.org/10.3109/13697137.2012.717994
  38. Pinkerton J, Harvey J, Lindsay R, Archer D, Pan K, Mirkin S. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014;99:2:189-198.  https://doi.org/10.1210/jc.2013-1707
  39. Kagan R, Abreu P, Andrews E. Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo. Postgrad Med. 2018;130:8:687-693.  https://doi.org/10.1080/00325481.2018.1520046
  40. Simon J, Liu J, Speroff L, Shumel B, Symons J. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol. 2003;188:1:92-99.  https://doi.org/10.1067/mob.2003.104
  41. Kazerooni T, Zolghadri J. The comparison of bleeding patterns with high-dose and low-dose hormone replacement therapy in postmenopausal women. Gynecol Endocrinol. 2004;19:2:64-68.  https://doi.org/10.1080/09513590400002318
  42. Barnabei V, Cochrane B, Aragaki A, Williams R, McGovern P, Young P, Wells E. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol. 2005;105:5 Pt 1:1063-1073. https://doi.org/10.1097/01.AOG.0000158120.47542.18
  43. Brynhildsen J, Hammar M. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. Menopause. 2002;9:2:137-144.  https://doi.org/10.1097/00042192-200203000-00009
  44. Limpaphayom K, Bunyavejchevin S. Clinical effects of 17 beta-estradiol and norethisterone acetate in postmenopausal Thai women. J Med Assoc Thai. 2000;83:4:407-416. 
  45. Mirkin S, Goldstein S, Archer D, Pickar J, Graham S, Bernick B. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR). Menopause. 2020;27:4:410-417.  https://doi.org/10.1097/GME.0000000000001480
  46. Rozenberg S, Pornel B, Koninckx P, Palacios S, Christiansen C. Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen. Hum Reprod. 2009;24:7:1739-1747. https://doi.org/10.1093/humrep/dep067
  47. Haines C, Chung T, Lau T. Sonographic measurement of endometrial thickness as a predictor of vaginal bleeding in women using continuous combined hormone replacement therapy. Gynecol Obstet Invest. 1997;44:3:187-190.  https://doi.org/10.1159/000291516
  48. Bassol S, Carranza-Lira S, Celis-Gonzalez C, Santoyo S, Murillo A, Martinez N, Santos J. The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women. Maturitas. 2005;50:3:189-195.  https://doi.org/10.1016/j.maturitas.2004.05.014
  49. Quereux C, Pornel B, Bergeron C, Ferenczy A. Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile. Maturitas. 2006;53:3:299-305.  https://doi.org/10.1016/j.maturitas.2005.05.015
  50. Gräser T, Römer T, Wiedey K, Janaud A. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric. 2001;4:4:332-342. 
  51. Mattsson L, Ipsen H, Granqvist C, Kokot-Kierepa M. Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy. Climacteric. 2015;18:3:419-425.  https://doi.org/10.3109/13697137.2014.999661
  52. Bergeron C, Nogales F, Rechberger T, Tatarchjuk T, Zipfel L. Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17beta-oestradiol and 2.5mg dydrogesterone: protection of the endometrium and amenorrhoea rate. Maturitas. 2010;66:2:201-205.  https://doi.org/10.1016/j.maturitas.2010.03.007
  53. Archer D, Bernick B, Mirkin S. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause. Expert Rev Clin Pharmacol. 2019;12:8:729-739.  https://doi.org/10.1080/17512433.2019.1637731
  54. Kingsberg S, Larkin L, Krychman M, Parish S, Bernick B, Mirkin S. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause. 2019;26:2:124-131.  https://doi.org/10.1097/GME.0000000000001194
  55. Mirkin S, Goldstein S, Archer D, Pickar J, Graham S, Bernick B. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR). Menopause. 2020;27:4:410-417.  https://doi.org/10.1097/GME.0000000000001480
  56. Pickar JH, Archer DF, Goldstein SR, Kagan R, Bernick B, Mirkin S. Uterine bleeding with hormone therapies in menopausal women: a systematic review. Climacteric. 2020;23:6:555-558.  https://doi.org/10.1080/13697137.2020.1806816
  57. Junge W, El-Samalouti V, Gerlinger C, Schaefers M. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. Eur J Obstet Gynecol Reprod Biol. 2009;147:2:195-200.  https://doi.org/10.1016/j.ejogrb.2009.09.004
  58. Constantine G, Goldstein S, Pickar J, Graham S, Bernick B, Mirkin S. SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms. J Endocr Soc. 2019;3(suppl 1):SAT-238. Published 2019 Apr 30.  https://doi.org/10.1210/js.2019-SAT-238
  59. Krikun G, Schatz F, Taylor R, Critchley HOD, Rogers PAW, Huang J, Lockwood CJ. Endometrial endothelial cell steroid receptor expression and steroid effects on gene expression. J Clin Endocrinol Metab. 2005;90:3:1812-1818. https://doi.org/10.1210/jc.2004-1814
  60. Lecce G, Meduri G, Ancelin M, Bergeron C, Perrot-Applanat M. Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J Clin Endocrinol Metab. 2001;86:3:1379-1386. https://doi.org/10.1210/jcem.86.3.7322
  61. Hickey M, Dwarte D, Fraser IS. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod. 2000;15:7:1509-1514. https://doi.org/10.1093/humrep/15.7.1509
  62. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:3:321-333.  https://doi.org/10.1001/jama.288.3.321
  63. Hickey M, Pillai G, Higham JM. Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding. Hum Reprod. 2003;18:5:1100-1106. https://doi.org/10.1093/humrep/deg171
  64. Mirkin S, Navarro F, Archer DF. Hormone therapy and endometrial angiogenesis. Climacteric. 2003;6:4:273-277. 
  65. Lockwood CJ, Runic R, Wan L, Krikun G, Demopolous R, Schatz F. The role of tissue factor in regulating endometrial haemostasis: implications for progestin-only contraception. Hum Reprod. 2000;15(suppl 3):144-151.  https://doi.org/10.1093/humrep/15.suppl_3.144
  66. Vincent AJ, Zhang J, Ostör A, Rogers PA, Affandi B, Kovacs G. Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding? Hum Reprod. 2002;17:5:1189-1198. https://doi.org/10.1093/humrep/17.5.1189
  67. Hickey M, Crewe J, Mahoney LA, Doherty DA, Fraser IS, Salamonsen LA. Mechanisms of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors. J Clin Endocrinol Metab. 2006;91:8:3189-3198. https://doi.org/10.1210/jc.2005-2748
  68. Hickey M, Crewe J, Goodridge JP, Witt CS, Fraser IS, Doherty D. Menopausal hormone therapy and irregular endometrial bleeding: a potential role for uterine natural killer cells? J Clin Endocrinol Metab. 2005;90:10:5528-5535. https://doi.org/10.1210/jc.2005-0688
  69. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJ. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med. 1981;305:27:1599-1605. https://doi.org/10.1056/NEJM198112313052701
  70. Goldstein SR. The endometrial echo revisited: have we created a monster? Am J Obstet Gynecol. 2004;191:4:1092-1096. https://doi.org/10.1016/j.ajog.2004.05.017
  71. Mirkin S, Archer DF, Taylor HS, Pickar JH, Komm BS. Differential effects of menopausal therapies on the endometrium. Menopause. 2014;21:8:899-908.  https://doi.org/10.1097/GME.0000000000000186
  72. Mirkin S, Wong BC, Archer DF. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005;84:2:485-491.  https://doi.org/10.1016/j.fertnstert.2005.01.129
  73. Mirkin S, Archer DF. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17beta-estradiol on thrombospondin-1 mRNA in Ishikawa cells. Fertil Steril. 2004;82:1:220-222.  https://doi.org/10.1016/j.fertnstert.2004.02.100
  74. von Holst T, Lang E, Winkler U, Keil D. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas. 2002;43:4:265-275.  https://doi.org/10.1016/s0378-5122(02)00203-7
  75. Rouskova D, Mittmann K, Schumacher U, Dietrich H, Zimmermann T. Effectiveness, tolerability and acceptance of an oral estradiol/levonorgestrel formulation for the treatment of menopausal complaints: a non-interventional observational study over six cycles of 28 days. Gynecol Endocrinol. 2014;30:10:712-716.  https://doi.org/10.3109/09513590.2014.925867 70
  76. Simon JA. Future developments in the medical treatment of abnormal uterine bleeding: what can we expect? Menopause. 2011;18:4:462-466.  https://doi.org/10.1097/gme.0b013e3182127b53

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.